allogeneic– tag –
-
Cartherics to File IND for Ovarian Cancer iPSC-Derived NK Cell Therapy CTH-401 After Asia Pacific Award
Cartherics Pty Ltd Australia Overview Australian biotech Cartherics Pty Ltd was recognized as the Emerging Leader in Allogeneic Cell Therapy at the Asia Pacific Cell & Gene Therapy Excellence Awards 2026. Leveraging its proprietary g... -
Gene-Edited iPSC-Derived CAR-T/NK Therapies Target Allogeneic Rejection for Off-the-Shelf Cancer Immunotherapy
MDPI Switzerland Overview Allogeneic T cell therapies represent a scalable, off-the-shelf alternative to autologous approaches, promising to overcome significant logistical and manufacturing limitations. The review highlights iPSC-derive... -
FDA Approves Orca-T, First Regulatory T-Cell Therapy to Improve Chronic GVHD-Free Survival in Blood Cancer Patients Undergoing Allogeneic HSCT
American Society of Clinical Oncology (ASCO) Post USA Overview The US FDA has approved Orca-T (Tregzi, Orca Bio), the first regulatory T-cell (Treg)-based immunotherapy to improve chronic graft-versus-host disease (GVHD)-free survival in... -
UniXell’s iPSC-Derived Parkinson’s Therapy UX-DA003 Cleared for US Clinical Trials by FDA
Parkinson's News Today USA Overview UniXell Biotechnology has received FDA Investigational New Drug (IND) clearance for UX-DA003, an allogeneic iPSC-derived dopaminergic neural progenitor cell therapy for Parkinson's disease, enabling th... -
FDA Approves Allogeneic Cell Therapy TREGZI for GVHD; New Advanced Cell Therapy Association Launches in Europe
RegMedNet UK Overview The FDA has approved Orca Bio's allogeneic cell therapy TREGZI (Orc-T®) for graft-versus-host disease (GVHD), based on positive Phase 3 Precision-T trial results, aiming to mitigate GVHD and reconstruct immunity. Si... -
CAR-T Cell Therapy for Autoimmune Diseases Achieves 40-60% Cost Reduction and Sub-7-Day Manufacturing Through Gene Editing and Process Optimization
Market Intelo USA Overview Advances in gene-editing technologies are significantly reducing alloreactivity risk in allogeneic CAR-T products and cutting production costs by an estimated 40-60%. Next-generation allogeneic platforms aim to... -
Syntax Bio and Applied StemCell Partner to Accelerate Allogeneic Cell Therapies with GMP-Compliant Hypoimmune iPSCs and Cellgorithm Platform
CRISPR Medicine News USA Overview Syntax Bio and Applied StemCell have forged a strategic collaboration to propel next-generation regenerative medicine by advancing stem cell innovation. Applied StemCell will supply GMP-compatible hypoim... -
UniXell Biotechnology Secures US FDA IND Clearance for Off-the-Shelf Parkinson’s Cell Therapy UX-DA003, Accelerating Dual China-US Clinical Development
BioPharma APAC USA Overview UniXell Biotechnology announced that its allogeneic iPSC-derived therapy UX-DA003 for Parkinson's disease has received Investigational New Drug (IND) approval from the US FDA. This approval enables the company... -
Syntax Bio & Applied StemCell Partner to Accelerate Allogeneic iPSC Therapies with Low-Immunogenicity Lines and Cellgorithm Platform
Manufacturing Chemist USA Overview Syntax Bio and Applied StemCell have formed a strategic partnership to accelerate programmable iPSC therapy development. This collaboration aims to address key challenges of immune recognition and manuf... -
iPSC-Derived Immune Cells Pave Way for Scalable Allogeneic T-Cell Therapy Platforms in Cancer Immunotherapy
MDPI Global Overview Allogeneic T-cell therapies are rapidly advancing as a promising strategy in cancer immunotherapy to overcome the logistical and manufacturing challenges inherent in autologous approaches. Crucially, induced pluripot...
